How to Improve Medication Adherence in Clinical Trials

Medication adherence is one of the quietest threats to a clinical trial’s success. A protocol can be well-designed, a site well-trained, and a participant well-intentioned, and the study can still produce muddy data because doses were missed, mistimed, or never taken at all. For sponsors and CROs, poor adherence inflates the sample size you need, weakens statistical power, and in the worst case turns a true treatment effect into a non-significant result.

This guide covers why participants miss doses, what poor adherence actually costs, the strategies that move the needle, and how modern monitoring technology, including AI-verified dosing, turns adherence from something you report after the fact into something you can manage in real time.

Why adherence matters more than most teams budget for

Non-adherence does not just add noise; it biases your results toward the null. When a meaningful share of participants in the treatment arm aren’t actually receiving the intended exposure, the measured difference between arms shrinks. To preserve power, you compensate the only way you can: by enrolling more participants, running longer, or both. Every one of those compensations costs money and time.

The effect compounds in three places:

• Statistical power. Diluted exposure means you need a larger N to detect the same effect, directly increasing recruitment and site costs.
• Data integrity. If you can’t distinguish a non-responder from a non-taker, your efficacy and safety signals are both harder to interpret, a problem regulators notice.
• Retention. Participants who fall behind on dosing are often the same ones who drift toward dropout. Adherence and retention are tightly linked, and losing a participant late in a study is far more expensive than supporting them early.

The throughline: adherence problems are cheapest to fix early, and most expensive to discover at database lock.

Why participants miss doses

Before reaching for a solution, it helps to name the actual failure modes. Most missed doses fall into a handful of patterns:

1. Forgetting. The most common and most solvable. Busy lives, complex regimens, and dosing schedules that don’t map onto daily routines.
2. Intentional non-adherence. Side effects, feeling better, or simply not believing the medication is helping. This one is behavioral, not logistical, and reminders alone won’t fix it.
3. Confusion about instructions. Take with food? Skip if a dose is missed? Ambiguity at the moment of dosing quietly erodes compliance.
4. Burden. Long in-person visits, awkward logging, or friction-heavy reporting tools train participants to disengage.
5. No feedback loop. When a participant has no signal that their input mattered, motivation fades. Confirmation is a surprisingly powerful adherence lever.

Notice that only some of these are about memory. A reminder-only solution addresses pattern 1 and leaves the rest untouched, which is why the most effective programs combine prompting, education, low-friction capture, and a human escalation path.

Seven strategies that measurably improve adherence

1. Simplify the regimen and the reporting

Every additional step between “it’s time to dose” and “the dose is logged” is a place to lose a participant. Reduce dosing complexity where the protocol allows, and make logging a dose take seconds, not minutes. The reporting experience is part of the regimen, whether or not your team thinks of it that way.

2. Meet participants on the channel they actually use

A reminder that arrives as a push notification, an SMS, and (when needed) an email will reach far more people than any single channel. Multi-channel, escalating reminders respect the reality that participants are not sitting in your portal waiting.

3. Close the loop with immediate confirmation

When a participant logs or records a dose and immediately sees that it counted, you’ve done two things: reinforced the behavior and given them evidence their effort matters. Studies of digital adherence tools consistently find that this sense of progress and acknowledgement supports sustained engagement and lowers attrition.

4. Move from self-report to objective evidence

Pill counts and paper diaries are cheap, but they measure what participants are willing to tell you, not what happened. Objective methods (MEMS caps, PK assays, and digital dose capture) replace recall with records. The trend across the industry is unmistakably toward timestamped, verifiable evidence.

5. Give study teams early visibility

The single most valuable thing a monitoring system can do is surface a developing problem before it becomes a withdrawal. When a coordinator sees a participant slipping at dose three instead of discovering it at the week-eight visit, a five-minute outreach call can save the data point, and often the participant.

6. Use observed-style verification where rigor matters

For high-stakes endpoints, directly observed therapy (DOT) has long been the gold standard. Its weakness is scale: it doesn’t fit decentralized or hybrid trials, and it burdens everyone involved. Asynchronous video dosing is the modern answer: a participant records a short clip of taking the dose, and software verifies it under fixed rules. You get much of DOT’s evidentiary strength without a clinician watching in real time. (This is exactly the approach behind our Dose Guarantee feature.)

7. Build an escalation workflow, not just an alert

An alert that no one owns is noise. The teams that succeed define who acts, when, and through which channel when adherence dips, and they let the system escalate automatically when the first outreach goes unanswered. Adherence is a workflow problem as much as a technology one.

What the evidence says about AI-supported adherence

There’s understandable skepticism about “AI for adherence,” so it’s worth being precise. The value isn’t the model in the abstract; it’s what the model makes possible at scale.

Reviews published in the digital-health literature have reported that AI-supported adherence tools improve medication-taking relative to standard care, with one 2025 review in Frontiers in Digital Health summarizing improvements across multiple studies and noting meaningfully higher verified adherence in groups using app-based, real-time tools compared with controls. The mechanisms behind those gains are mundane in the best way: well-timed reminders, instant confirmation, and early flags that let humans intervene.

In other words, AI’s contribution to adherence is operational leverage. It lets a small clinical operations team apply observed-therapy-grade rigor and timely outreach across hundreds of participants and dozens of sites, work that would be impossible to do manually.

How Trialsights approaches adherence

Trialsights treats adherence as something to prove, not just report. Two capabilities do the heavy lifting:

• Participant Compliance: including Dose Guarantee, our AI-verified video dosing. A participant records one continuous front-camera video (pill on the tongue, swallow) and the AI verifies the dose under version-pinned rules. It’s the scalable alternative to in-person DOT, and the evidence is timestamped and tamper-evident.
• Lab Surveillance: automated coordinator check-ins, smart multi-channel reminders, and role-based escalation, so the human side of the workflow closes the loop instead of chasing it.

Both feed an audit trail designed to align with 21 CFR Part 11 expectations, so the adherence number you report at the end of the study is one you can defend.

Where to start

You don’t need to overhaul your operations to improve adherence. Start with the highest-leverage move for your study:

• If you’re running a decentralized or hybrid trial, prioritize objective, remote-friendly dose capture over self-report.
• If you’re losing participants mid-study, invest first in early visibility and a real escalation workflow.
• If your endpoint is adherence-sensitive, evaluate observed-style verification before you finalize your monitoring plan.

Adherence is rarely fixed by a single tactic. But teams that combine low-friction capture, multi-channel reminders, objective verification, and a human escalation path consistently turn a soft, after-the-fact metric into a managed, defensible one.

---

Want to see adherence monitoring on your own protocol? Schedule a demo and we’ll walk through AI-verified dosing, site surveillance, and the audit trail on a live demo trial.